China Journal of Leprosy and Skin Diseases ›› 2022, Vol. 38 ›› Issue (2): 135-138.doi: 10.12144/zgmfskin202202135

• Reviews • Previous Articles    

Cutaneous adverse effects of immune-checkpoint inhibitors

LIU Yunyi, JIANG Peiyu, LI Min, TAO Meng, LIU Yixuan, ZHANG Jiawen, NAN Yuqing, XU Yang   

  1. Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Online:2022-02-15 Published:2021-12-22
  • Contact: XU Yang, E-mail: cardioos@163.com

Abstract: The  immune-checkpoint inhibitors (ICIs) are the most important development on oncotherapy in the past decade, which includes anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1(PD-L1) antibodies. However, they bring a new spectrum of immune-related adverse events (irAEs), of which cutaneous adverse effects are most common. This article reviews the skin-related adverse reactions and management of ICIs.

Key words: immune-checkpoint inhibitors, immune-related adverse events, skin